In vivo studies have shown that the RIPK1 inhibitor Nec-1, RIPK3 inhibitor GSK’872, and MLKL inhibitor Necrosulfonamide (NSA) significantly reduced the severity of IBD. This evidence concerns the gene MLKL and inflammatory bowel disease.